CoChat

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

Open access

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Formation of pathogenic antibodies is a major problem in replacement therapies for inherited protein deficiencies. For example, antibodies to coagulation factors (‘inhibitors’) seriously complicate treatment of haemophilia. While immune tolerance induction (ITI) protocols have been developed, inhibitors against factor IX (FIX) are difficult to eradicate due to anaphylactic reactions and nephrotic syndrome and thus substantially elevate risks for morbidity and mortality. However, hepatic gene transfer with an adeno‐associated virus (AAV) serotype 8 vector expressing FIX (at levels of ≥4% of normal) rapidly reversed pre‐existing high‐titre inhibitors in haemophilia B mice, eliminated antibody production by B cells, desensitized from anaphylaxis (even if protein therapy was resumed) and provided long‐term correction. High levels of FIX protein suppressed memory B cells and increased Treg induction, indicating direct and indirect mechanisms of suppression of inhibitor formation. Persistent presence of Treg was required to prevent relapse of antibodies. Together, these data suggest that hepatic gene transfer‐based ITI provides a safe and effective alternative to eradicate inhibitors. This strategy may be broadly applicable to reversal of antibodies in different genetic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201302859

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mutation and dose dependence of antibody responses against hFIX in hemophilia B mice C3H/HeJ F9−/− mice (HB) and C3H/HeJ F9−/− mice transgenic for mutant hFIX proteins R180W (HB-180), LS 338 (HB-338), and G381E (HB-CH) were challenged with 1 IU hFIX protein starting with an intraperitoneal injection following by 5 weekly intravenous injections. Anti-hFIX IgG1 titers (ng/ml) one week following the last hFIX protein injection.Inhibitor (Bethesda) titers one week following the last hFIX protein injection.Kaplan-Meier survival plot for HB, HB-180, HB-338, HB-CH mice following weekly challenge with hFIX protein. HB mice were co-administered antihistamine and PAF antagonist on the fifth and sixth exposures to hFIX protein.HB mice were immunized with a range of hFIX protein levels (0.1 to 3 IU, which corresponds to 0.5 to 15 µg total hFIX protein per dose). Shown are anti-hFIX IgG1 titers (ng/ml) at the end of challenge as a function of hF.IX dose.Bethesda titers (BU/ml) as a function of hF.IX dose in HB mice.Anti-hFIX IgE levels (ng/ml) as a function of hF.IX dose in HB mice. Graphs in A, B, D-F show data for individual animals as well as averages ± SD; n = 4–6/experimental group.
Figure 1 Mutation and dose dependence of antibody responses against hFIX in hemophilia B mice C3H/HeJ F9−/− mice (HB) and C3H/HeJ F9−/− mice transgenic for mutant hFIX proteins R180W (HB-180), LS 338 (HB-338), and G381E (HB-CH) were challenged with 1 IU hFIX protein starting with an intraperitoneal injection following by 5 weekly intravenous injections. Anti-hFIX IgG1 titers (ng/ml) one week following the last hFIX protein injection.Inhibitor (Bethesda) titers one week following the last hFIX protein injection.Kaplan-Meier survival plot for HB, HB-180, HB-338, HB-CH mice following weekly challenge with hFIX protein. HB mice were co-administered antihistamine and PAF antagonist on the fifth and sixth exposures to hFIX protein.HB mice were immunized with a range of hFIX protein levels (0.1 to 3 IU, which corresponds to 0.5 to 15 µg total hFIX protein per dose). Shown are anti-hFIX IgG1 titers (ng/ml) at the end of challenge as a function of hF.IX dose.Bethesda titers (BU/ml) as a function of hF.IX dose in HB mice.Anti-hFIX IgE levels (ng/ml) as a function of hF.IX dose in HB mice. Graphs in A, B, D-F show data for individual animals as well as averages ± SD; n = 4–6/experimental group.CC BY · PubMed Central
Figure 2 Reversal of inhibitors and of anaphylaxis by hepatic AAV8-hF9 gene transfer C3H/HeJ F9−/− mice (HB) were immunized with hFIX protein to generate pre-existing high-titer inhibitors. A control group of immunized mice were then left alone to follow hFIX antibodies over the course of the experiment. Following confirmation of inhibitors, mice were treated with 1 × 1011 vg of an AAV8-hF9 vector (n = 8) and were bled 4, 8, 16, and 18 weeks following injection of vector. Samples from immunized control HB (n = 5) and vector-treated HB mice were used for ELISA measurements. Experimental time line.Anti-hFIXIgG1 titers (ng/ml).IgE titers (ng/ml).Inhibitor titers (BU/ml).Circulating levels of hFIX protein (ng/ml).Restoration of hemostasis was assessed by measurement of coagulation activity by activated partial thromboplastin time (aPTT, in seconds). Data points in A–F are average ± SD.Kaplan-Meier survival plot of 1 × 1011 vg AAV8-hF9 vector treated mice following weekly challenge with hFIX protein.
Figure 2 Reversal of inhibitors and of anaphylaxis by hepatic AAV8-hF9 gene transfer C3H/HeJ F9−/− mice (HB) were immunized with hFIX protein to generate pre-existing high-titer inhibitors. A control group of immunized mice were then left alone to follow hFIX antibodies over the course of the experiment. Following confirmation of inhibitors, mice were treated with 1 × 1011 vg of an AAV8-hF9 vector (n = 8) and were bled 4, 8, 16, and 18 weeks following injection of vector. Samples from immunized control HB (n = 5) and vector-treated HB mice were used for ELISA measurements. Experimental time line.Anti-hFIXIgG1 titers (ng/ml).IgE titers (ng/ml).Inhibitor titers (BU/ml).Circulating levels of hFIX protein (ng/ml).Restoration of hemostasis was assessed by measurement of coagulation activity by activated partial thromboplastin time (aPTT, in seconds). Data points in A–F are average ± SD.Kaplan-Meier survival plot of 1 × 1011 vg AAV8-hF9 vector treated mice following weekly challenge with hFIX protein.CC BY · PubMed Central
Figure 3 Reversal of B- and T-cell responses against hFIX by hepatic AAV8-hF9 gene transfer B-cell ELISpot assays specific for hFIX antibody secreting were performed on both bone marrow and spleen cells from C3H/HeJ F9−/− mice immunized against hF.X. Results are presented as spots forming units (SFU) per 106 cells with representative wells presented to the right. B-cell ELISpots for hFIX antibody secreting bone marrow cells (AAV8 F9 versus Early Con p = 0.0022 and AAV8 F9 versus Late Con p = 0.0286).B-cell ELISpots for hFIX antibody secreting splenocytes (AAV8 F9 versus Early Con p = 0.0043 and AAV8 F9 versus Late Con p = 0.0195). Early con (early controls) refers to mice sacrificed shortly after the immunization protocol, i.e. the time point of vector treatment. Late Con (late controls) are immunized untreated mice that were followed in parallel to vector treated mice.Cytokine responses specific to hF.IX. Splenocytes (1 × 105 per well) were cultured in vitro without or with hFIX protein (10 μg/ml) and harvested 48 h later for mRNA extraction and cDNA synthesis and ran on qPCR array with genes associated with Th1, Th2, or Treg responses. Results are presented as fold change compared to unstimulated cells. Bar graphs indicate average ± SD with n = 4/experimental group (IL-4 Control versus AAV8 F9 p = 0.0196). The students 2-tailed T test was used to determine statistical significance.
Figure 3 Reversal of B- and T-cell responses against hFIX by hepatic AAV8-hF9 gene transfer B-cell ELISpot assays specific for hFIX antibody secreting were performed on both bone marrow and spleen cells from C3H/HeJ F9−/− mice immunized against hF.X. Results are presented as spots forming units (SFU) per 106 cells with representative wells presented to the right. B-cell ELISpots for hFIX antibody secreting bone marrow cells (AAV8 F9 versus Early Con p = 0.0022 and AAV8 F9 versus Late Con p = 0.0286).B-cell ELISpots for hFIX antibody secreting splenocytes (AAV8 F9 versus Early Con p = 0.0043 and AAV8 F9 versus Late Con p = 0.0195). Early con (early controls) refers to mice sacrificed shortly after the immunization protocol, i.e. the time point of vector treatment. Late Con (late controls) are immunized untreated mice that were followed in parallel to vector treated mice.Cytokine responses specific to hF.IX. Splenocytes (1 × 105 per well) were cultured in vitro without or with hFIX protein (10 μg/ml) and harvested 48 h later for mRNA extraction and cDNA synthesis and ran on qPCR array with genes associated with Th1, Th2, or Treg responses. Results are presented as fold change compared to unstimulated cells. Bar graphs indicate average ± SD with n = 4/experimental group (IL-4 Control versus AAV8 F9 p = 0.0196). The students 2-tailed T test was used to determine statistical significance.CC BY · PubMed Central
Figure 4 Reversal of B- and T-cell responses against hFIX by hepatic gene transfer is vector dose-dependent Hemophilia B mice were immunized with hFIX protein and subsequently given an IV injection of 1 × 1010 (n = 7) or 2 × 109 vg (n = 3) of AAV8-hF9 vector. Anti-hFIX IgG1 titers (ng/ml).Inhibitor titers (BU/ml).Circulating hFIX protein levels (ng/ml).Coagulation times (aPTT in sec) as a function of time after vector treatment.Kaplan-Meier survival curves were generated for 2 × 109 and 1 × 1010 vg treated HB mice following weekly challenge with hFIX protein. Data points in A-D are average ± SD.
Figure 4 Reversal of B- and T-cell responses against hFIX by hepatic gene transfer is vector dose-dependent Hemophilia B mice were immunized with hFIX protein and subsequently given an IV injection of 1 × 1010 (n = 7) or 2 × 109 vg (n = 3) of AAV8-hF9 vector. Anti-hFIX IgG1 titers (ng/ml).Inhibitor titers (BU/ml).Circulating hFIX protein levels (ng/ml).Coagulation times (aPTT in sec) as a function of time after vector treatment.Kaplan-Meier survival curves were generated for 2 × 109 and 1 × 1010 vg treated HB mice following weekly challenge with hFIX protein. Data points in A-D are average ± SD.CC BY · PubMed Central
Figure 5 Levels of hFIX antigen impact activation of memory B cells Haemophilia B mice were immunized with hFIX in adjuvant followed by splenocyte isolation 3 weeks later. Plasma cells were depleted using CD138 beads from Miltenyi Biotech, and cells were cultured for 6 days with 0, 0.1, 1 or 10 IU/ml hFIX protein.hFIX-specific B-cell ELISpot was performed on cells following 6 days of culture and results are reported as spot forming units (SFU)/106 cells with a representative experiment shown to the right. Statistical analysis was performed using one-way ANOVA (p = 0.0051) with Bonferroni's multiple comparison test (p < 0.05 as a cut off for significance and confidence levels). Data are averaged from three independent experiments using pooled splenocytes from four mice immunized with hFIX protein. Data in bar graph are average ± SD.
Figure 5 Levels of hFIX antigen impact activation of memory B cells Haemophilia B mice were immunized with hFIX in adjuvant followed by splenocyte isolation 3 weeks later. Plasma cells were depleted using CD138 beads from Miltenyi Biotech, and cells were cultured for 6 days with 0, 0.1, 1 or 10 IU/ml hFIX protein.hFIX-specific B-cell ELISpot was performed on cells following 6 days of culture and results are reported as spot forming units (SFU)/106 cells with a representative experiment shown to the right. Statistical analysis was performed using one-way ANOVA (p = 0.0051) with Bonferroni's multiple comparison test (p < 0.05 as a cut off for significance and confidence levels). Data are averaged from three independent experiments using pooled splenocytes from four mice immunized with hFIX protein. Data in bar graph are average ± SD.CC BY · PubMed Central
Figure 6 Treg-mediated suppression of anti-hFIX formation is vector dose dependent Vector injected (2 × 109, 1 × 1010 or 1 × 1011 vg AAV8-ApoE/hAAT hF9) C3H/HeJ and naïve mice were Treg donors. Following purification using magnetic activated cell sorting 1 × 106 Treg were injected into naïve recipient C3H/HeJ mice which were challenged the following by with 1 IU hFIX protein in adjuvant.Anti-hFIX IgG1 (ng/ml) titres 3 weeks following subcutaneous challenge of hFIX in adjuvant. Data (average ± SD) is from vector treated Treg (n = 4 per vector dose) and naïve Treg controls (n = 8). The Student's 2-tailed T test was used to determine statistical significance (naïve vs. 1010 p = 0.0022, naïve vs. 1011 p = 0.0008 and 1010 vs. 1011 p = 0.0286).
Figure 6 Treg-mediated suppression of anti-hFIX formation is vector dose dependent Vector injected (2 × 109, 1 × 1010 or 1 × 1011 vg AAV8-ApoE/hAAT hF9) C3H/HeJ and naïve mice were Treg donors. Following purification using magnetic activated cell sorting 1 × 106 Treg were injected into naïve recipient C3H/HeJ mice which were challenged the following by with 1 IU hFIX protein in adjuvant.Anti-hFIX IgG1 (ng/ml) titres 3 weeks following subcutaneous challenge of hFIX in adjuvant. Data (average ± SD) is from vector treated Treg (n = 4 per vector dose) and naïve Treg controls (n = 8). The Student's 2-tailed T test was used to determine statistical significance (naïve vs. 1010 p = 0.0022, naïve vs. 1011 p = 0.0008 and 1010 vs. 1011 p = 0.0286).CC BY · PubMed Central
Figure 7 Continued suppression by Treg is required for long-term tolerance Three groups of DTR-FoxP3 mice were challenged with 1 IU hFIX in adjuvant and divided into control, no vector, (green), early DT, DT immediately following vector (blue), and late DT, DT two months following vector (red).Mice were bled at the indicated time points for flow cytometry measurement of %CD25+FoxP3+/CD4+Treg.Anti-hFIX IgG1 titers (ng/ml) as a function of time. Vertical lines indicate respective times of DT administration for early (blue) and late (red) groups. Data points in B-C are average ± SD; n = 3–5/experimental group.
Figure 7 Continued suppression by Treg is required for long-term tolerance Three groups of DTR-FoxP3 mice were challenged with 1 IU hFIX in adjuvant and divided into control, no vector, (green), early DT, DT immediately following vector (blue), and late DT, DT two months following vector (red).Mice were bled at the indicated time points for flow cytometry measurement of %CD25+FoxP3+/CD4+Treg.Anti-hFIX IgG1 titers (ng/ml) as a function of time. Vertical lines indicate respective times of DT administration for early (blue) and late (red) groups. Data points in B-C are average ± SD; n = 3–5/experimental group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 116

Metadata

Authors
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W.
Affiliations
  • University of Florida Health (US)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Herzog, Roland W.
Venue
EMBO Molecular Medicine
Published
2013-09-16
Volume
5
Issue
11
Pages
1698-1709
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2158153222
Cited by
116
References
64
Citations by year
2026: 3 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 11 · 2017: 20 · 2016: 12 · 2015: 11 · 2014: 13 · 2013: 2
FWCI
9.09
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health (P01 HD078810 (KAH and RWH), R01 AI051390 (RWH), F32 HL096281 (DMM))
  • Howard Hughes Medical Institute
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
hemophilia B, factor IX inhibitors, immune tolerance induction, AAV8, hepatic gene transfer, gene therapy, memory B cells, regulatory T cells, anaphylaxis, factor replacement therapy
MeSH terms
Dependovirus, Animals, Antibodies, Antibody Formation, B-Lymphocytes, Hemophilia B, Factor IX, Genetic Vectors, Humans, Liver, Male, Mice, Inbred C3H, Mice, Inbred C57BL, Genetic Therapy, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.